Search Results 1121-1130 of 17867 for monoclonal antibody

1. Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients - Mayo Clinic

   Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from ...

2. Mouth sores caused by cancer treatment: How to cope - Mayo Clinic

   ... resistant prostate cancer (mCRPC) · Monoclonal antibody medicines for cancer: How they work · Multiple myeloma · Myxofibrosarcoma · Neuroblastoma · No appetite?

3. Atezolizumab Immunotherapy in Patients With Advanced NSCLC (AJCC 7th Edition) - Mayo Clinic

   Prior severe infusion reaction to a monoclonal antibody. Severe, active co-morbidity, defined as follows: Significant history of uncontrolled cardiac ...

4. Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

   Pertuzumab, an anti-HER2 humanized monoclonal antibody ... In this respect, anti-ErbB2 monoclonal antibody 4D5 specifically inhibits the growth of tumor cells ...

5. A Study to Evaluate Immune and Hematopoietic Cell Assessment in Clonal B Cell Conditions - Mayo Clinic

   The purpose of this study is to evaluate the immune and hematopoietic compartments in patients with monoclonal B cell lymphocytosis (MBL) and chronic ...

6. Inotuzumab Ozogamicin In Treating Younger Patients With Relapsed Or Refractory CD22 Positive B Acute Lymphoblastic Leukemia - Mayo Clinic

   Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a ... monoclonal antibody with the exception of blinatumomab; patients must have ...

7. A Study to Evaluate EAA181 to Treat Newly-diagnosed Multiple Myeloma - Mayo Clinic

   ≥ 200 mg/24 hours of monoclonal protein on a 24-hour urine protein electrophoresis. ... Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease).

8. A Study Evaluating the Effectiveness and Safety of Axicabtagene Ciloleucel in Subjects with High-Risk Large B-Cell Lymphoma - Mayo Clinic

   2 cycles of an anti-CD20 monoclonal antibody (unless investigator determines that tumor is CD20 negative) and anthracycline-containing regimen (e.g., DA ...

9. A Study Of VENTANA TROP2 (EPR20043) Device In Non-Small Cell Lung Cancer (NSCLC) - Mayo Clinic

   ... Monoclonal Antibody, RUO). Exclusion Criteria: The amount of tumor tissue is insufficient to cut and mount the required number of tissue sections for use in ...

10. Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    ... monoclonal antibody (mAb). - Must be naïve to treatment with B-cell maturation antigen (BCMA)-targeted therapy. - Must be eligible to receive the ...